Pipeline
Deep Breadth: GSK Doubles Down on COPD and Asthma
With the recent approval of Breo Ellipta, a new combination product and delivery device for COPD and asthma patients – plus three more drugs currently under review at FDA – GSK hopes to build on its historic strength, and largest business area, with a new generation of respiratory products ...Read more
Digital Pharma
Will CEOs Embrace Social Media in 2014?
Depending who you listen to, as many as seven out of 10 CEOs are still to be convinced about social media. But with a plethora of recent studies emphasizing its strategic usefulness, Peter Houston asks if that figure will change in 2014 ...Read more
Patient Outcomes Research
Breaking Down PCORI’s $1BN Funding Commitment
The Patient-Centered Outcomes Research Institute (PCORI) has approved a two-year commitment to spend more than $1 billion in funding for comparative effectiveness research (CER) projects. But most of the money will go to paying for studies on how to improve teamwork among doctors, or the ways in which doctors communicate with patients about potential treatments ...Read more
Pharmaceutical Executive editorial staff proudly introduces PharmExec TV, their latest high quality pertinent content in a brand new industry-breaking format. Tune In Now
Video
Lilly Touts Rich Phase II and Phase III Pipeline
Despite the disappointment of edivoxetine's Phase III failure, Lilly has other promising drug candidates entering late stages of development. In this video interview, Dr. Jan Lundberg, EVP science and technology and president Lilly Research Labs, Lilly & Co., highlights Lilly's pipeline work on Alzheimer’s, psoriasis, oncology and diabetes drugs ...View Here
New E-Book- Lifecycle Solutions: Positioning Pharmaceuticals For Commercial Success
Time is risk. If time to market is slowed then the cost for a company is lost revenues, profits, and ultimately lost opportunities for patients. The message is clear. To compete and win, companies must wrest more value from every stage of a new product’s tightly projected lifecycle. Download Now
Global
Pharm Exec Global Digest — Personalized Medicine Special
Personalized medicines: Are they worth it?; Pathology in the era of personalized medicine; Clinical trial data disclosure — has Europe bitten off more than it can chew?; China: recruiting amid the corruption fallout; And more! ...Read more
|
